Oncogenic Mutations of PIK3CA in Human Cancers

Cited by (292)

Items 101–200 of 292

1. Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations
   Ursula Grazini, Aleksandra A. Markovets, Lucy Ireland, Daniel J. O’Neill, Benjamin Phillips, Man Xu, Matthias Pfeifer, Tereza Vaclová, Matthew J. Martin, Ludovic Bigot et al. · 2024 · Clinical Cancer Research
2. PIK3CA is recurrently mutated in canine mammary tumors, similarly to in human mammary neoplasia
   Maja L. Arendt, Sharadha Sakthikumar, Malin Melin, Ingegerd Elvers, Patricio Rivera, Majbritt Larsen, Sara Saellström, Frode Lingaas, Henrik Rönnberg, Kerstin Lindblad‐Toh · 2023 · Scientific Reports
3. Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein
   John M. Ketcham, Stephen J. Harwood, Ruth Aranda, Athenea N. Aloiau, Briana M. Bobek, David M. Briere, Aaron C. Burns, Kersti Caddell Haatveit, Andrew Calinisan, Jeff Clarine et al. · 2024 · Journal of Medicinal Chemistry
4. Role of the PI3K/AKT signaling pathway in the cellular response to Tumor Treating Fields (TTFields)
   Anat Klein-Goldberg, Tali Voloshin, Efrat Zemer Tov, Rom Paz, Lina Somri-Gannam, Alexandra Volodin, Lilach Koren, Lena Lifshitz, Aviv Meir, Ayelet Shabtay‐Orbach et al. · 2025 · Cell Death and Disease
5. Phosphoinositide 3-kinase pathways and autophagy require phosphatidylinositol phosphate kinases
   Suyong Choi, Xander Houdek, Richard Allen Anderson · 2018 · Advances in Biological Regulation
6. A Pilot Study to Non-Invasively Track PIK3CA Mutation in Head and Neck Cancer
   Henri Schmidt, Arutha Kulasinghe, Richard J. N. Allcock, Lit Yeen Tan, Elisa Mokany, Liz Kenny, Chamindie Punyadeera · 2018 · Diagnostics
7. ERBB4 Mutation Analysis: Emerging Molecular Target for Melanoma Treatment
   Christopher C. Lau, Keith J. Killian, Yardena Samuels, Udo Rudloff · 2013 · Methods in molecular biology
8. Phosphatidylinositol 3-kinase (PI3KCA) Oncogene Mutation Analysis and Gene Expression Profiling in Primary Breast Cancer Patients
   Mahesh Kandula, Kalyan Kumar Chennaboina, Y.S. Ammi Raju, Suryanarayana Raju · 2013 · Asian Pacific Journal of Cancer Prevention
9. Molecular Tumor Profiling for Prediction of Response to Anticancer Therapies
   Zenta Walther, Jeffrey Sklar · 2011 · The Cancer Journal
10. PIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysis
    Zhi-Ming Shao, Yi‐Rong Liu, Yizhou Jiang, Ke‐Da Yu, Wen‐Jia Zuo · 2014 · OncoTargets and Therapy
11. miR‐212‐5p exerts tumor promoter function by regulating the Id3/PI3K/Akt axis in lung adenocarcinoma cells
    Fang‐fang Chen, Ning Sun, Yin Wang, Haiyan Xi, Yang Yang, Bai‐zeng Yu, Xiao‐jun Li · 2020 · Journal of Cellular Physiology
12. Emerging Intrinsic Therapeutic Targets for Metastatic Breast Cancer
    Jiawei Li, Eyleen L. K. Goh, Ji He, Yan Li, Zhimin Fan, Zhigang Yu, Peng Yuan, Dong‐Xu Liu · 2023 · Biology
13. PIK3CAandTP53mutations predict overall survival of stage II/III colorectal cancer patients
    Ajian Li, Huaguang Li, Erjiang Tang, Wei Wu, Ying Chen, Huihong Jiang, Moubin Lin, Lu Yin · 2018 · World Journal of Gastroenterology
14. Mutation analysis of the EGFR pathway genes, EGFR, RAS, PIK3CA, BRAF, and AKT1 , in salivary gland adenoid cystic carcinoma
    Kosuke Saida, Takayuki Murase, Mayuko Ito, Kana Fujii, Hisashi Takino, Ayako Masaki, Daisuke Kawakita, Kei Ijichi, Yuichiro Tada, Kimihide Kusafuka et al. · 2018 · Oncotarget
15. Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma
    Fung‐Yu Huang, Danny K.-H. Wong, Vivien Wai Man Tsui, Wai‐Kay Seto, Lung‐Yi Mak, Tan To Cheung, Keane K. Y. Lai, M.-F. Yuen · 2019 · BMC Cancer
16. Genomic analysis of cervical carcinoma identifies Alpelisib as a therapeutic option for PIK3CA ‐mutant cervical carcinoma via the PI3K/AKT pathway
    Wei Ye, Shitong Lin, Wenhua Zhi, Tian Chu, Binghan Liu, Ting Peng, Miaochun Xu, Wencheng Ding, Canhui Cao, Peng Wu · 2023 · Journal of Medical Virology
17. Identification of natural product as selective PI3Kα inhibitor against NSCLC: multi-ligand pharmacophore modeling, molecular docking, ADME, DFT, and MD simulations
    Debojyoti Halder, Subham Das, Ramaiah Selladurai Jeyaprakash · 2023 · Molecular Diversity
18. Molecular mechanisms underlying the regulation of tumour suppressor genes in lung cancer
    Lee Jy, Richie Rashmin Bhandare, Sai H. S. Boddu, AFZAL BASHA SHAIK, Lakshmana Prabu Saktivel, Gaurav Gupta, Poonam Negi, Muna M. Barakat, Sachin Kumar Singh, Kamal Dua et al. · 2024 · Biomedicine & Pharmacotherapy
19. PI3K Pathway in Gynecologic Malignancies
    Helga Birgitte Salvesen, Henrica M.J. Werner, Camilla Krakstad · 2013 · American Society of Clinical Oncology Educational Book
20. Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients
    Cristina Bozzao, Dora Varvara, Marilidia Piglionica, Rosanna Bagnulo, Giovanna Forte, Margherita Patruno, Silvana Russo, Domenico Piscitelli, Alessandro Stella, Nicoletta Resta · 2012 · The International Journal of Biological Markers
21. PI 3K‐dependent multiple myeloma cell survival is mediated by the PIK 3 CA isoform
    Claudia Hofmann, Thorsten Stühmer, Nadine Schmiedl, Reinhard Wetzker, Anja Mottok, Andreas Rosenwald, Christian Langer, Josip Zovko, Manik Chatterjee, Hermann Einsele et al. · 2014 · British Journal of Haematology
22. Application of Machine Learning to Development of Copy Number Variation-based Prediction of Cancer Risk
    Xiaofan Ding, Shui‐Ying Tsang, Siu-Kin Ng, Hong Xue · 2014 · Genomics Insights
23. For Better or Worse: The Potential for Dose Limiting the On-Target Toxicity of PI 3-Kinase Inhibitors
    Christina Maree Buchanan, Kate Lee, Peter Robin Shepherd · 2019 · Biomolecules
24. Circulating tumor cells: indicators of cancer progression, plasticity and utility for therapies
    Tamás Richárd Linkner, Zsófia Brigitta Nagy, Alexandra Kalmár, Eszter Farkas, Fruzsina Bányai, Nikolett Szakállas, István Takács, Béla Molnár · 2025 · Pathology & Oncology Research
25. Clinicopathological significance of EGFR pathway gene mutations and CRTC1/3–MAML2 fusions in salivary gland mucoepidermoid carcinoma
    Maki Morita, Takayuki Murase, Yoshihide Okumura, Kaori Ueda, Yuma Sakamoto, Ayako Masaki, Daisuke Kawakita, Yuichiro Tada, Ken‐ichi Nibu, Yasuyuki Shibuya et al. · 2020 · Histopathology
26. Landscape of Genetic Mutations in Appendiceal Cancers
    Marian Constantin, Cristina Mătanie, Livia Petrescu, Alexandra Bolocan, Octavian Andronic, Coralia Bleoţu, Mihaela Magdalena Mitache, Sorin Ioan Tudorache, Corneliu Ovidiu Vrâncianu · 2023 · Cancers
27. Non-invasive imaging of PI3K/Akt/mTOR signalling in cancer.
    Snehal M. Gaikwad, Pritha Ray · 2012 · Europe PMC (PubMed Central)
28. miR‑142‑5p inhibits pancreatic cancer cell migration and invasion by targeting PIK3CA
    Jing Zhu, Leilei Zhou, Bin Wei, Zhaoye Qian, Jiru Wang, Hongxia Hui, Yuan Sun · 2020 · Molecular Medicine Reports
29. Econazole nitrate inhibits PI3K activity and promotes apoptosis in lung cancer cells
    Chao Dong, Runxiang Yang, Hongjian Li, Kunbin Ke, Chunxiang Luo, Fang Yang, Xinan Shi, Ying Zhu, Xu Liu, Man‐Hon Wong et al. · 2017 · Scientific Reports
30. Angiosarcoma: a systematic review of biomarkers in diagnosis, prognosis, and therapeutic strategies
    Huyen Thuc Tran Luong, Sofie Vercammen, Ario de Marco, H. de Rooster, Antonio Cosma · 2025 · Frontiers in Oncology
31. Systemic Metabolism, Its Regulators, and Cancer: Past Mistakes and Future Potential
    Jeff M.P. Holly, Kalina M. Biernacka, Claire M. Perks · 2019 · Frontiers in Endocrinology
32. Vitamin C and B3 as New Biomaterials to Alter Intestinal Stem Cells
    Yi-Jun Qi, Jo Lohman, K. Bratlie, Nathan Peroutka-Bigus, B. Bellaire, M. Wannemuehler, Kyoung-Jin Yoon, T. Barrett, Qun Wang · 2019 · Journal of Biomedical Materials Research. Part A
33. PIK3CA hypomethylation plays a key role in activation of the PI3K/AKT pathway in esophageal cancer in Chinese patients
    Wei-Feng Wang, Yan Xie, Zhi-Hua Zhou, Zheng‐Hong Qin, Junchao Wu, Jingkang He · 2013 · Acta Pharmacologica Sinica
34. Targeting PI3K in cancer treatment: A comprehensive review with insights from clinical outcomes
    Md. Takdir Hossain, Md. Arafat Hossain · 2025 · European Journal of Pharmacology
35. The structure-based cancer-related single amino acid variation prediction
    Jiajun Liu, Chin‐Sheng Yu, Hsiao-Wei Wu, Yu-Jen Chang, Chih‐Peng Lin, Chih‐Hao Lu · 2021 · Scientific Reports
36. Any Role of PIK3CA and PTEN Biomarkers in the Prognosis in Oral Squamous Cell Carcinoma?
    Anna Starzyńska, Paulina Adamska, Aleksandra Sejda, Monika Sakowicz‐Burkiewicz, Łukasz Jan Adamski, Giulia Marvaso, Piotr Wychowański, Barbara Alicja Jereczek‐Fossa · 2020 · Life
37. Large‐scale genomic sequencing reveals adaptive opportunity of targeting mutated‐PI3Kα in early and advanced HER2‐positive breast cancer
    Linwei Guo, Xiaoguang Li, Yunsong Yang, Xun‐Xi Lu, Xiangchen Han, Guan‐Tian Lang, Li Chen, Zhi‐Ming Shao, Xin Hu · 2021 · Clinical and Translational Medicine
38. Cryo-EM structures reveal two allosteric inhibition modes of PI3KαH1047R involving a re-shaping of the activation loop
    Xiuliang Huang, Kailiang Wang, Jing Han, Xiumei Chen, Zhenglin Wang, Tianlun Wu, Bo Yu, Feng Zhao, Xinjuan Wang, Huijuan Li et al. · 2024 · Structure
39. T-Cell-Specific Loss of the PI-3-Kinase p110α Catalytic Subunit Results in Enhanced Cytokine Production and Antitumor Response
    Laura Aragoneses-Fenoll, Gloria Ojeda, María Montes‐Casado, Yeny Acosta‐Ampudia, Umberto Dianzani, Pilàr Portolés, José María Rojo · 2018 · Frontiers in Immunology
40. Alteration in glycolytic/cholesterogenic gene expression is associated with bladder cancer prognosis and immune cell infiltration
    Yuying Zhang, Baoyi Zhu, Yi Cai, Sihua Zhu, Hongjun Zhao, Xiaoling Ying, Chonghe Jiang, Jianwen Zeng · 2022 · BMC Cancer
41. Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors
    Gordon W. Rewcastle, Sharada Kolekar, Christina Maree Buchanan, Swarna A. Gamage, Anna C. Giddens, Kit Yee Tsang, Jackie D. Kendall, Ripudaman Singh, Woo-Jeong Lee, Greg C. Smith et al. · 2017 · Oncotarget
42. Targeting the PI3K Pathway in Gynecologic Malignancies
    Monica Avila, Michaela Onstad Grinsfelder, Melissa M. Pham, Shannon Neville Westin · 2022 · Current Oncology Reports
43. Single-molecule studies reveal regulatory interactions between master kinases PDK1, AKT1, and PKC
    Moshe T. Gordon, Brian P. Ziemba, Joseph J. Falke · 2021 · Biophysical Journal
44. Diagnostic and therapeutic biomarkers in colorectal cancer: a review.
    Jéssica Vieira de Assis, Lucélia Antunes Coutinho, Ifeoluwa Temitayo Oyeyemi, Oyetunde Timothy Oyeyemi, Rafaella Fortini Queiroz Grenfell · 2022 · PubMed Central
45. Multiple Metabolic Alterations Exist in Mutant PI3K Cancers, but Only Glucose Is Essential as a Nutrient Source
    Rebecca Rachael Foster, Sue Griffin, Suzanne Grooby, Ruth E. Feltell, Cindy Christopherson, Monica Chang, John J. Sninsky, Shirley Kwok, Chris J Torrance · 2012 · PLoS ONE
46. Next‐generation sequencing in salivary gland carcinoma: Targetable alterations lead to a therapeutic advantage—Multicenter experience
    Assaf Moore, Yael Bar, Corinne Maurice‐Dror, Inna Ospovat, Michal Sarfaty, Yasmin Korzets, Hadar Goldvaser, Noa Gordon, Salem Billan, Orit Gutfeld et al. · 2019 · Head & Neck
47. Clear Cell Squamous Cell Carcinoma of the Maxillary Gingiva Associated with PIK3CA and HRAS Mutations: Report of a Case and Literature Review
    Katsutoshi Hirose, Takumi Shibahara, Akari Teramoto, Yu Usami, Sawako Ono, Yuri Iwamoto, Shumei Murakami, Kaori Oya, Narikazu Uzawa, Daisuke Motooka et al. · 2023 · Head and Neck Pathology
48. Transcriptomic analysis associated with reversal of cisplatin sensitivity in drug resistant osteosarcoma cells after a drug holiday
    Divya Niveditha, Harshita Sharma, Syamantak Majumder, Sudeshna Mukherjee, Rajdeep Chowdhury, Shibasish Chowdhury · 2019 · BMC Cancer
49. Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer
    Anne Marie McCarthy, Nitya Kumar, Wei Wu He, Susan Regan, Michaela Welch, Beverly Moy, Anthony John Iafrate, Andrew Tan Chan, Aditya Bardia, Katrina Armstrong · 2020 · BMC Cancer
50. Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007 – present)
    Elena Sacco, Michela Spinelli, Marco Vanoni · 2012 · Expert Opinion on Therapeutic Patents
51. Current and future molecular diagnostics in non-small-cell lung cancer
    Chun Man Li, Wing Ying Chu, Di Lun Wong, Hin Fung Tsang, Nancy B. Y. Tsui, Charles Ming Lok Chan, Vivian Weiwen Xue, Parco M. Siu, Benjamin Yat‐Ming Yung, Lawrence Chan et al. · 2015 · Expert Review of Molecular Diagnostics
52. The High Frequency of PIK3CA Mutations in Iranian Breast Cancer Patients
    Ghasem Azizi Tabesh, Pantea Izadi, Forouzandeh Fereidooni, Àmirnader Emami Razavi, Javad Tavakkoly‐Bazzaz · 2016 · Cancer Investigation
53. The combined analysis of solid and liquid biopsies provides additional clinical information to improve patient care
    Ana Finzel, Helen Sadik, Gregori Ghitti, Jean‐François Laes · 2018 · Journal of Cancer Metastasis and Treatment
54. 11C-Labeled Pictilisib (GDC-0941) as a Molecular Tracer Targeting Phosphatidylinositol 3-Kinase (PI3K) for Breast Cancer Imaging
    Na Han, Yaqun Jiang, Yongkang Gai, Qingyao Liu, Lujie Yuan, Yichun Wang, Mengting Li, Yongxue Zhang, Xiaoli Lan · 2019 · Contrast Media & Molecular Imaging
55. Multiplexed molecular profiling of lung cancer with malignant pleural effusion using next generation sequencing in Chinese patients
    Xingya Ruan, Yonghua Sun, Wei Wang, Jianwei Ye, Daoyun Zhang, Ziying Gong, Mingxia Yang · 2020 · Oncology Letters
56. Alpelisib and radiotherapy treatment enhances Alisertib-mediated cervical cancer tumor killing.
    Yaman Tayyar, Adi Idris, Josif Vidimce, Danyelle Assis Ferreira, Nigel A.J. McMillan · 2021 · PubMed Central
57. Detection of breast cancer-related point-mutations using screen-printed and gold-plated electrochemical sensor arrays suitable for point-of-care applications
    Vanessa Thoeny, Eva Melnik, Malahat Asadi, Pooyan Mehrabi, Thomas G. M. Schalkhammer, Walter Pulverer, Thomas Maier, Giorgio C. Mutinati, Peter Alexander Lieberzeit, Rainer Hainberger · 2022 · Talanta Open
58. Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers
    Lizbeth DeSelm, Bayard R. Huck, Ruoxi Lan, Constantin Neagu, Justin R. Potnick, Yufang Xiao, Xiaoling Chen, Reinaldo C. Jones, Thomas E. Richardson, Brian H. Heasley et al. · 2021 · Journal of Medicinal Chemistry
59. Overexpression of wild type or a Q311E mutant MB21D2 promotes a pro‐oncogenic phenotype in HNSCC
    Daniel Esguerra Gracilla, Praveen Kumar Korla, Ming‐Tsung Lai, An‐Jen Chiang, Wen‐Shiung Liou, Jim Jinn‐Chyuan Sheu · 2020 · Molecular Oncology
60. Molecular basis and therapeutic targets in prostate cancer: A comprehensive review
    Florentina Claudia Militaru, Valentin Militaru, Nicolae Crişan, Ioana Corina Bocșan, Anghel Adrian Udrea, Andreea M. Catana, Enikő Kutasi, Mariela Sanda Militaru · 2023 · Biomolecules and Biomedicine
61. BI-69A11 enhances susceptibility of colon cancer cells to mda-7/IL-24-induced growth inhibition by targeting Akt
    Ipsita Pal, Siddik Sarkar, Shashi Rajput, Kaushik Kumar Dey, S Chakraborty, Rupesh Dash, Swadesh Kumar Das, Devanand Sarkar, Elisa Barile, Surya Kanta De et al. · 2014 · British Journal of Cancer
62. Downregulation of miR-144 by triptolide enhanced p85α−PTEN complex formation causing S phase arrest of human nasopharyngeal carcinoma cells
    Chien-Wei Wu, Shyang‐Guang Wang, Meng‐Liang Lin, Shih‐Shun Chen · 2019 · European Journal of Pharmacology
63. Common cancer biomarkers of breast and ovarian types identified through artificial intelligence
    Shrikant Pawar, Tuck Onn Liew, Aditya Stanam, Chandrajit Lahiri · 2020 · Chemical Biology & Drug Design
64. Targeting PI3K, FGFR, CDK4/6 Signaling Pathways Together With Cytostatics and Radiotherapy in Two Medulloblastoma Cell Lines
    Monika Lukoseviciute, Henrietta Maier, Eleni Poulou‐Sidiropoulou, Erika Rosendahl, Stefan Holzhauser, Tina Dalianis, Ourania N. Kostopoulou · 2021 · Frontiers in Oncology
65. Clinical significance of molecular subtypes of gastrointestinal tract adenocarcinoma
    E. Ignatova, Evgenii M. Kozlov, Maxim V. Ivanov, Vladislav Mileyko, Sofia Menshikova, Henian Sun, Mikhail Yu. Fedyanin, Alexey Alexandrovich Tryakin, Ivan Sokratovich Stilidi · 2022 · World Journal of Gastrointestinal Oncology
66. Reconciling the Biological and Transcriptional Variability of Hepatoblastoma with Its Mutational Uniformity
    Edward V. Prochownik · 2021 · Cancers
67. Comparison of different noble metal-based screen-printed sensors for detection of PIK3CA point-mutations as biomarker for circulating tumor DNA
    Vanessa Thoeny, Eva Melnik, Thomas Maier, Steffen Kurzhals, Christian G. Derntl, Walter Pulverer, Giorgio C. Mutinati, Malahat Asadi, Pooyan Mehrabi, Melanie Huetter et al. · 2023 · Electrochimica Acta
68. Structural effects of morpholine replacement in ZSTK474 on Class I PI3K isoform inhibition: Development of novel MEK/PI3K bifunctional inhibitors
    Marcian E. Van Dort, Youngsoon Jang, Christopher A. Bonham, Kevin Heist, Dilrukshika S.W. Palagama, Lucas McDonald, Edward Z. Zhang, Thomas L. Chenevert, Gary D. Luker, Brian Dale Ross · 2021 · European Journal of Medicinal Chemistry
69. Recombinase polymerase amplification in combination with electrochemical readout for sensitive and specific detection of PIK3CA point mutations
    Vanessa Thoeny, Eva Melnik, Melanie Huetter, Malahat Asadi, Pooyan Mehrabi, Thomas G. M. Schalkhammer, Walter Pulverer, Thomas Maier, Giorgio C. Mutinati, Peter Alexander Lieberzeit et al. · 2023 · Analytica Chimica Acta
70. Plasma PIK3CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancer.
    Huiping Li, Yaping Xu, Fangyuan Zhao, Guohong Song, Hope S. Rugo, Yan Zhang, Ling Yang, Xiaoran Liu, Bin Shao, Liang Yang et al. · 2018 · Europe PMC (PubMed Central)
71. Insights into the pathological mechanisms of p85α mutations using a yeast-based phosphatidylinositol 3-kinase model
    María D. Oliver, Teresa Fernández‐Acero, Sandra Luna, Isabel Rodríguez‐Escudero, Marı́a Molina, Rafael Pulido, Vı́ctor J. Cid · 2017 · Bioscience Reports
72. An Overview of the Mechanisms of HPV-Induced Cervical Cancer: The Role of Kinase Targets in Pathogenesis and Drug Resistance
    Medha Karnik, SubbaRao V. Tulimilli, Preethi G. Anantharaju, Anjali Devi S. Bettadapura, Suma M. Natraj, Habeeb Shaik Mohideen, Sinisa Dovat, Arati K. Sharma, SubbaRao V. Madhunapantula · 2026 · Cancers
73. Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective
    Lena Weiss, Kathrin Heinrich, Duojie Zhang, Klara Dorman, Katharina Rühlmann, Korbinian Hasselmann, Frederick Klauschen, Joerg Kumbrink, Andreas Jung, Martina Rudelius et al. · 2023 · Journal of Cancer Research and Clinical Oncology
74. Structure–activity optimization of Deferasirox–derived aroyl hydrazones: Synthesis, DFT characterization, and mechanistic insights into selective anticancer activity against colon and breast cancer
    Ömer Dilek, Muzaffer Dükel, Fatema Zarzour, Çiğdem Karabacak Atay, Tahir Tilki · 2025 · Bioorganic Chemistry
75. The sensitivity and efficacy method of PIK3CA exon 9 E545A as a high diagnostic accuracy in breast cancer
    Desriani Desriani, Fuad Al-Ahwani · 2017 · Journal of Genetic Engineering and Biotechnology
76. La vía canónica PI3K/AKT/mTOR y sus alteraciones en cáncer
    Clínica Internacional San Borja. Lima, Perú. Universidad Peruana de Ciencias Aplicadas (UPC), Facultad de Medicina. Lima, Perú. Médico Oncólogo, Maestría en Medicina, Franklin Aldecoa-Bedoya, J. Ávila, Universidad Peruana de Ciencias Aplicadas (UPC), Facultad de Medicina. Lima, Perú. Médico cirujano, Coordinador de Línea de Estructura y Función · 2021 · Horizonte Médico (Lima)
77. Bioanalysis of alpelisib using liquid chromatography–tandem mass spectrometry and application to pharmacokinetic study
    Seop Lee, Min‐Soo Kim, Jong‐Woo Jeong, Jung‐woo Chae, Tae‐Sung Koo, Han‐Joo Maeng, Suk‐Jae Chung, Kyeong‐Ryoon Lee, Yoon‐Jee Chae · 2022 · Journal of Analytical Science & Technology
78. Familial CCM Genes Might Not Be Main Drivers for Pathogenesis of Sporadic CCMs-Genetic Similarity between Cancers and Vascular Malformations
    Jun Zhang, Jacob Croft, Alexander Le · 2023 · Journal of Personalized Medicine
79. Genomic Alterations of Tumors in HER2-Low Breast Cancers
    Yi‐Fang Tsai, Chi‐Cheng Huang, Chih‐Yi Hsu, Chin-Jung Feng, Yen‐Shu Lin, Ta‐Chung Chao, Jiun‐I Lai, Pei‐Ju Lien, Chun‐Yu Liu, Jen‐Hwey Chiu et al. · 2024 · International Journal of Molecular Sciences
80. Estimating the Frequency of Single Point Driver Mutations across Common Solid Tumours
    Madeleine Darbyshire, Zachary D. du Toit, Mark F. Rogers, Tom R. Gaunt, Colin Campbell · 2019 · Scientific Reports
81. Clinicopathological Significance of PTEN Expression and Its Prognostic Effect in Colorectal Adenocarcinoma Patients
    Zohreh Mirzapour Abbas abadi, Fatemeh Samiee Rad, Dariush Hamedi Asl, Babak Rahmani, Mahmood Soleimani Dodaran, Amir Peimani · 2022 · Iranian journal of pathology
82. PIK3CA promotes proliferation and motility but is unassociated with lymph node metastasis or prognosis in esophageal squamous cell carcinoma
    Shutao Zheng, Chenchen Yang, Mang Lu, Qing Liu, Tao Liu, Fang Dai, Xiangpeng Gao, Ilyar Sheyhidin, Xiaomei Lu · 2016 · Human Pathology
83. Experimental verification of a predicted novel microRNA located in human PIK3CA gene with a potential oncogenic function in colorectal cancer
    Ali Jason Saleh, Bahram Mohammad Soltani, Sadat Dokanehiifard, Abdallah Ahmad Medlej, Mahmood Tavallaei, Seyed Javad Mowla · 2016 · Tumor Biology
84. New molecular targets in canine hemangiosarcoma—Comparative review and future of the precision medicine
    Karolina Kapturska, Aleksandra Pawlak · 2023 · Veterinary and Comparative Oncology
85. Altered expression of anti-apoptotic protein Api5 affects breast tumorigenesis
    Abhijith Kuttanamkuzhi, Debiprasad Panda, Radhika Malaviya, Gautami Gaidhani, Mayurika Lahiri · 2023 · BMC Cancer
86. A role for SETD2 loss in tumorigenesis through DNA methylation dysregulation
    Hira Javaid, Alessandro Barberis, Olga Chervova, Isar Nassiri, Vitaly Voloshin, Yusuke Sato, Seishi Ogawa, Benjamin Peter Fairfax, Francesca Meteora Buffa, Timothy C. Humphrey · 2023 · BMC Cancer
87. Recreational Physical Activity and Risk of Ovarian Cancer: a Meta-analysis
    Limin Zhou · 2014 · Asian Pacific Journal of Cancer Prevention
88. New Mechanisms of mTOR Pathway Activation in KIT-mutant Malignant GISTs
    Jerzy P. Lasota, Artur Kowalik, Anna Felisiak-Gołąbek, Sebastian Zięba, Zeng-Feng Wang, Markku Miettinen · 2017 · Applied immunohistochemistry & molecular morphology
89. Reciprocal regulation of Daxx and PIK3CA promotes colorectal cancer cell growth
    Yen‐Sung Huang, Chang‐Chieh Wu, Che‐Chang Chang, Shiu-Feng Kathy Huang, Hong-Yi Kuo, Hsiu‐Ming Shih · 2022 · Cellular and Molecular Life Sciences
90. Inositol and PIP2/PIP3 Ratio: At the Crossroad of the Biodynamic Interface Between Cells and Their Microenvironment
    Guglielmo Lentini, Alessandro Querqui, Alessandro Giuliani, Roberto Verna, Mariano Bizzarri · 2025 · Biomolecules
91. Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer
    Shunsuke Kondo, Masaomi Tajimi, Tomohiko Funai, Koichi Inoue, Hiroya Asou, Vinay Kumar Ranka, Volker Wacheck, Toshihiko Doi · 2020 · Investigational New Drugs
92. Targeting MEK/COX-2 axis improve immunotherapy efficacy in dMMR colorectal cancer with PIK3CA overexpression
    Kunwei Peng, Yongxiang Liu, Shousheng Liu, Zining Wang, Huanling Zhang, Wenzhuo He, Ya‐Nan Jin, Lei Wang, Xiaojun Xia, Liangping Xia · 2024 · Cellular Oncology
93. Discovery of a novel aminopyrazine series as selective PI3Kα inhibitors
    Bernard C. Barlaam, Sabina C. Cosulich, Martina Fitzek, Hervé Germain, Stephen A. Green, Lyndsey L. Hanson, Craig Steven Harris, Urs J. Hancox, Kevin Hudson, Christine Lambert‐van der Brempt et al. · 2017 · Bioorganic & Medicinal Chemistry Letters
94. Identification of the Binding Sites on Rab5 and p110beta Phosphatidylinositol 3-kinase
    Dielle E. Whitecross, Deborah H. Anderson · 2017 · Scientific Reports
95. Increased Expression of Phosphatidylinositol 3-Kinase p110α and Gene Amplification of PIK3CA in Nasopharyngeal Carcinoma
    Wai Kien Yip, Pei Yuan He, Maizaton Atmadini Abdullah, Suryati Mohd Yusoff, Heng Fong Seow · 2015 · Pathology & Oncology Research
96. De-regulation of aurora kinases by oncogenic HPV; implications in cancer development and treatment
    Kemi Hannah Oladipo, Joanna L. Parish · 2025 · Tumour Virus Research
97. Predictive and prognostic biomarkers in gastrointestinal tract tumours
    Klaudia M. Nowak, Runjan Chetty · 2024 · Pathology
98. Potential of Tyrosine Kinase Receptor TIE-1 as Novel Therapeutic Target in High-PI3K-Expressing Ovarian Cancer
    Xuewei Zhang, Masumi Ishibashi, Kazuyuki Kitatani, Shogo Shigeta, Hideki Tokunaga, Masafumi Toyoshima, Muneaki Shimada, Nobuo Yaegashi · 2020 · Cancers
99. Multi-gene custom panels for the characterisation of metastatic colorectal carcinoma in clinical practice: express the role of PIK3CA mutations
    Dario de Biase, Umberto Malapelle, Antonio De Leo, Thais Maloberti, Michela Visani, Pasquale Pisapia, Giorgia Acquaviva, Francesco Pepe, Gianluca Russo, Antonino Iaccarino et al. · 2021 · Journal of Clinical Pathology
100. Comprehensive identification of a migrasomes-associated long non-coding RNA signature to predict the prognosis and treatment options in colon adenocarcinoma
     Zhen Zheng, Hui Liu, Quan Xu, Wei Cui, Kaitai Liu · 2025 · Discover Oncology